Millipore Sigma Vibrant Logo

219370 Coagulation Factor VIIa, Human Plasma

Coagulation Factor VIIa, Human Plasma, is a native coagulation factor VIIa prepared from human Factor VII using human Factor XIIa, which was removed after activation.

Coagulation Factor VIIa, Human Plasma : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.
View Products on Sigmaaldrich.com
219370
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
219370-10UG
Récupération des données relatives à la disponibilité...
—
Exécution et livraison retardées Exécution et livraison retardées
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Ampoule plast. 10 μg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewNative coagulation factor VIIa from human plasma prepared from human Factor VII using human Factor XIIa, which was removed after activation. In the coagulation process, after complexing with tissue factor and membrane phospholipids, Factor VIIa activates Factors IX and X to the enzymatically active Factors IXa and Xa. Provides a crossover point between the extrinsic and intrinsic pathways.
      Catalogue Number219370
      Brand Family Calbiochem®
      References
      ReferencesBroze, G.J. 1994. In Haemostasis and Thrombosis, 3rd Edition(Bloom, et al. Eds.) Churchill Livingstone, Edinburgh, p 349.
      Majerus, P.W., et al. 1990. In The Pharmacological Basis of Therapeutics, 8th Edition (Gilman, A.G., et al. Eds.) Pergamon Press, New York, p 1311.
      Product Information
      EC number3.4.21.21
      FormLiquid
      FormulationIn 100 mM NaCl, 20 mM Tris-HCl, pH 7.5.
      Quality SegmentMQ100
      Applications
      Biological Information
      Purity≥95% by SDS-PAGE
      SourcePrepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      Specific Activity≥25,000 PEU/mg protein (clotting assay). Clotting activity is determined by comparison to a standard curve produced using normal pooled human plasma
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial use aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade ITEM Number
      Référence GTIN
      219370-10UG 04055977202250

      Documentation

      Coagulation Factor VIIa, Human Plasma FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Coagulation Factor VIIa, Human Plasma Certificats d'analyse

      TitreNuméro de lot
      219370

      Références bibliographiques

      Aperçu de la référence bibliographique
      Broze, G.J. 1994. In Haemostasis and Thrombosis, 3rd Edition(Bloom, et al. Eds.) Churchill Livingstone, Edinburgh, p 349.
      Majerus, P.W., et al. 1990. In The Pharmacological Basis of Therapeutics, 8th Edition (Gilman, A.G., et al. Eds.) Pergamon Press, New York, p 1311.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision05-June-2008 RFH
      DescriptionNative coagulation factor VIIa from human plasma prepared from human Factor VII using human Factor XIIa, which was removed after activation. Factor VIIa provides a crossover point between the extrinsic and intrinsic pathways. Prepared from human Factor VII using Human Factor XIIa.
      FormLiquid
      FormulationIn 100 mM NaCl, 20 mM Tris-HCl, pH 7.5.
      Concentration Label Please refer to vial label for lot-specific concentration
      SourcePrepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
      EC number3.4.21.21
      Purity≥95% by SDS-PAGE
      Specific activity≥25,000 PEU/mg protein (clotting assay). Clotting activity is determined by comparison to a standard curve produced using normal pooled human plasma
      Storage Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial use aliquot and freeze (-70°C).
      Toxicity Standard Handling
      ReferencesBroze, G.J. 1994. In Haemostasis and Thrombosis, 3rd Edition(Bloom, et al. Eds.) Churchill Livingstone, Edinburgh, p 349.
      Majerus, P.W., et al. 1990. In The Pharmacological Basis of Therapeutics, 8th Edition (Gilman, A.G., et al. Eds.) Pergamon Press, New York, p 1311.